Antimicrobial

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD

First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food...

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...

EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology

SALT LAKE CITY, Jan. 30, 2025 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life,...

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data...

Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act’s Medicare Negotiation Program

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business,...

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial...

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec....

error: Content is protected !!